Jubilant Ingrevia (JUBLINGREA) Q1 25/26 earnings summary

Executive summary

• Specialty Chemicals business delivered double-digit year-on-year growth and stable quarter-on-quarter performance, with ongoing cost optimization and margin improvements boosting profitability.

• EBITDA rose 29% year-on-year and profit after tax increased 54% year-on-year, driven by cost initiatives and improved product mix.

• Specialty and Nutrition segments now contribute 63% of total revenue and 90% of EBITDA, highlighting their strategic importance.

• Global chemical sector is emerging from an inventory phase; specialty chemicals see volume growth, while commodity segments face demand challenges.

• Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with unqualified limited review reports.

Financial highlights

• Q1 FY26 consolidated revenue was ₹1,037.95 crore, up from ₹1,024.34 crore in Q1 FY25, with volumes growing 5% year-on-year.

• EBITDA for the quarter was ₹153 crore, a 29% year-on-year increase, with a margin of 15%, the highest Q1 margin in four years.

• PAT for the quarter was ₹75 crore, up 54% year-on-year, with EPS at ₹4.75.

• Net debt as of June 30 was ₹700 crore; net debt-to-EBITDA ratio stable at 1.18x (TTM basis).

• Specialty Chemicals segment revenue grew 11% year-on-year, with EBITDA up 52% and margin at 27%.

Outlook and guidance

• FY26 expected to see continued growth, led by specialty chemicals, nutrition, and recovery in acetyls.

• Lean 2.0 cost efficiency initiatives target annualized savings exceeding ₹100 crore in FY26.

• On track to deliver a major CDMO order in early 2026, expected to accelerate growth.

• Management maintains view of reaching ₹6,500 crore peak revenue by FY27, with 70%-80% capacity utilization.

• Continued investment in renewable energy to meet growing power needs and sustainability goals.